ArticleJournal of cancer research and clinical oncology2026
Comparison of spread patterns and survival outcomes in uterine carcinosarcoma versus grade 3 endometrioid endometrial cancer.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the clinicopathologic characteristics, dissemination patterns, and survival outcomes of uterine carcinosarcoma (CS) and grade 3 endometrioid adenocarcinoma (G3EAC), focusing on nodal distribution and the impact of complete surgical staging.
methodsThis retrospective cohort study included 105 patients (43 CS, 62 G3EAC) who underwent primary surgical treatment at a single tertiary center between 2000 and 2016. A focused analysis was performed on a high-quality subgroup of 80 patients (76.2%) who underwent systematic pelvic and para-aortic lymphadenectomy. Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier methods, and independent prognostic factors were evaluated via Cox proportional hazards regression models.
resultsCS patients were significantly older than G3EAC patients (p = 0.005). While CS showed lower rates of deep myometrial invasion (44.2% vs. 67.7%; p = 0.016), it was associated with significantly higher positive peritoneal cytology (30.8% vs. 7.0%; p = 0.002). Overall lymph node metastasis rates were comparable between the groups (35.9% vs. 24.6%; p = 0.230). CS was associated with a significantly lower 5-year PFS (35.6% vs. 63.4%; p = 0.042), particularly in Stage IA disease (median PFS 7.7 months), and a trend toward lower 5-year OS (41.1% vs. 64.0%; p = 0.088). Multivariable analysis identified advanced age as the sole independent predictor of poor prognosis (OS HR 1.043, p = 0.021; PFS HR 1.039, p = 0.032). Notably, combined chemoradiotherapy (CRT) effectively eliminated the survival gap between histologies (5-year OS: 72.7% for CS vs. 70.0% for G3EAC; p = 0.590).
conclusionUterine carcinosarcoma exhibits minimal local invasion but high systemic aggressiveness. Traditional markers of local spread, such as myometrial invasion, are less predictive for CS. Systematic surgical staging remains essential, and multimodal adjuvant CRT is crucial to mitigating the inherent survival disadvantage of CS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.